UNLABELLED: Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (≥1 risk factor) were transitioned to denosumab or a monthly oral BP. Denosumab-treated subjects had significantly greater increases in bone mineral density and decreases in bone turnover in this 12-month study. INTRODUCTION: A clinical need exists to manage patients who are suboptimally adherent to oral BPs and remain at higher risk for fracture. Here, we compare the effects on bone mineral density (BMD) and bone turnover of transitioning such patients to denosumab or monthly oral BP (ibandronate or risedronate). METHODS: In two previous multicenter, open-label studies, postmenopausal women ≥55 years previously treated with, though suboptimally adherent to, a daily or weekly BP were randomized to denosumab 60 mg subcutaneously every 6 months (N = 852) or oral BP 150 mg monthly (N = 851) for 12 months. In this combined post-hoc analysis, a subset of higher risk subjects was identified, and the percentage changes from baseline in BMD and serum C-telopeptide of type I collagen (sCTX-1) were assessed. RESULTS: In the overall population, denosumab was associated with greater gains in BMD at 12 months than monthly oral BP at the total hip, femoral neck, and lumbar spine (p < 0.0001 for all). In higher risk subjects, denosumab led to greater gains in BMD than oral BPs at the total hip (2.2 vs 0.8 %), femoral neck (1.8 vs 0.3 %), and lumbar spine (3.7 vs 1.4 %) (p < 0.0001 for all). Denosumab also led to greater decreases in sCTX-1 in the overall population and higher risk subjects at months 1 and 6 (p < 0.0001 for both). Adverse events and serious adverse events were generally similar between treatment groups. CONCLUSIONS: Transitioning to denosumab was well tolerated and more effective in increasing BMD and reducing bone turnover than cycling to a monthly oral BP treatment in subjects who remained at higher fracture risk despite suboptimal BP treatment.
RCT Entities:
UNLABELLED: Managing osteoporoticpatients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (≥1 risk factor) were transitioned to denosumab or a monthly oral BP. Denosumab-treated subjects had significantly greater increases in bone mineral density and decreases in bone turnover in this 12-month study. INTRODUCTION: A clinical need exists to manage patients who are suboptimally adherent to oral BPs and remain at higher risk for fracture. Here, we compare the effects on bone mineral density (BMD) and bone turnover of transitioning such patients to denosumab or monthly oral BP (ibandronate or risedronate). METHODS: In two previous multicenter, open-label studies, postmenopausal women ≥55 years previously treated with, though suboptimally adherent to, a daily or weekly BP were randomized to denosumab 60 mg subcutaneously every 6 months (N = 852) or oral BP 150 mg monthly (N = 851) for 12 months. In this combined post-hoc analysis, a subset of higher risk subjects was identified, and the percentage changes from baseline in BMD and serum C-telopeptide of type I collagen (sCTX-1) were assessed. RESULTS: In the overall population, denosumab was associated with greater gains in BMD at 12 months than monthly oral BP at the total hip, femoral neck, and lumbar spine (p < 0.0001 for all). In higher risk subjects, denosumab led to greater gains in BMD than oral BPs at the total hip (2.2 vs 0.8 %), femoral neck (1.8 vs 0.3 %), and lumbar spine (3.7 vs 1.4 %) (p < 0.0001 for all). Denosumab also led to greater decreases in sCTX-1 in the overall population and higher risk subjects at months 1 and 6 (p < 0.0001 for both). Adverse events and serious adverse events were generally similar between treatment groups. CONCLUSIONS: Transitioning to denosumab was well tolerated and more effective in increasing BMD and reducing bone turnover than cycling to a monthly oral BP treatment in subjects who remained at higher fracture risk despite suboptimal BP treatment.
Authors: Paul D Miller; Michael R McClung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper Journal: J Bone Miner Res Date: 2005-03-14 Impact factor: 6.741
Authors: James A Simon; Christopher Recknor; Alfred H Moffett; Jonathan D Adachi; Edward Franek; E Michael Lewiecki; Michael R McClung; Carlos A Mautalen; Sergio Ragi-Eis; Geoffrey C Nicholson; Christian Muschitz; Ranuccio Nuti; Ove Törring; Andrea Wang; Cesar Libanati Journal: Menopause Date: 2013-02 Impact factor: 2.953
Authors: Ego Seeman; Pierre D Delmas; David A Hanley; Deborah Sellmeyer; Angela M Cheung; Elizabeth Shane; Ann Kearns; Thierry Thomas; Steven K Boyd; Stephanie Boutroy; Cesar Bogado; Sharmila Majumdar; Michelle Fan; Cesar Libanati; Jose Zanchetta Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Kristi Reynolds; Hema N Viswanathan; Cynthia D O'Malley; Paul Muntner; Teresa N Harrison; T Craig Cheetham; Jin-Wen Y Hsu; Deborah T Gold; Stuart Silverman; Andreas Grauer; Donald E Morisky Journal: Ann Pharmacother Date: 2012-04-17 Impact factor: 3.154
Authors: Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone Journal: J Bone Miner Res Date: 2009-01 Impact factor: 6.741
Authors: Judith Finigan; Diana M Greenfield; Aubrey Blumsohn; Rosemary A Hannon; Nicola F Peel; Guirong Jiang; Richard Eastell Journal: J Bone Miner Res Date: 2008-01 Impact factor: 6.741
Authors: Chris Recknor; Edward Czerwinski; Henry G Bone; Sydney L Bonnick; Neil Binkley; Santiago Palacios; Alfred Moffett; Suresh Siddhanti; Irene Ferreira; Prayashi Ghelani; Rachel B Wagman; Jesse W Hall; Michael A Bolognese; Claude-Laurent Benhamou Journal: Obstet Gynecol Date: 2013-06 Impact factor: 7.661
Authors: A D Anastasilakis; S A Polyzos; A Gkiomisi; Z G Saridakis; D Digkas; I Bisbinas; G T Sakellariou; A Papatheodorou; P Kokkoris; P Makras Journal: Osteoporos Int Date: 2015-05-20 Impact factor: 4.507
Authors: Jin Kyun Park; Andrea Fava; John Carrino; Filippo Del Grande; Antony Rosen; Francesco Boin Journal: Arthritis Rheumatol Date: 2016-01 Impact factor: 10.995
Authors: E Cairoli; S Palmieri; G Goggi; L Roggero; M Arosio; I Chiodini; C Eller-Vainicher Journal: J Endocrinol Invest Date: 2018-01-16 Impact factor: 4.256